AU2021252151A1 - Aptamers for use in the treatment of coronaviridae infections - Google Patents

Aptamers for use in the treatment of coronaviridae infections Download PDF

Info

Publication number
AU2021252151A1
AU2021252151A1 AU2021252151A AU2021252151A AU2021252151A1 AU 2021252151 A1 AU2021252151 A1 AU 2021252151A1 AU 2021252151 A AU2021252151 A AU 2021252151A AU 2021252151 A AU2021252151 A AU 2021252151A AU 2021252151 A1 AU2021252151 A1 AU 2021252151A1
Authority
AU
Australia
Prior art keywords
aptamer
receptor
seq
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021252151A
Other languages
English (en)
Inventor
Peter GÖTTEL
Annekathrin Haberland
Johannes Müller
Gerd Wallukat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Cures GmbH
Original Assignee
Berlin Cures GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Cures GmbH filed Critical Berlin Cures GmbH
Priority claimed from PCT/EP2021/059328 external-priority patent/WO2021205012A1/en
Publication of AU2021252151A1 publication Critical patent/AU2021252151A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2021252151A 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections Pending AU2021252151A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20168929 2020-04-09
EP20168929.6 2020-04-09
EP20176023.8 2020-05-22
EP20176023 2020-05-22
EP20180781 2020-06-18
EP20180781.5 2020-06-18
EP20204036 2020-10-27
EP20204036.6 2020-10-27
PCT/EP2021/059328 WO2021205012A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Publications (1)

Publication Number Publication Date
AU2021252151A1 true AU2021252151A1 (en) 2022-12-08

Family

ID=84191962

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021252151A Pending AU2021252151A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Country Status (11)

Country Link
US (1) US12606828B2 (enExample)
EP (1) EP4133083A1 (enExample)
JP (1) JP2023521361A (enExample)
KR (1) KR20220166337A (enExample)
CN (1) CN115768895A (enExample)
AU (1) AU2021252151A1 (enExample)
BR (1) BR112022020439A2 (enExample)
CA (1) CA3175067A1 (enExample)
IL (1) IL297155A (enExample)
MX (1) MX2022012618A (enExample)
ZA (1) ZA202212179B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3007984T3 (en) * 2021-04-09 2025-03-21 Berlin Cures GmbH Aptamers for use in the treatment of coronaviridae infections
KR102937192B1 (ko) * 2023-01-25 2026-03-17 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508473A (ja) * 2005-08-26 2009-03-05 アーケミツクス・コーポレイシヨン 高親和性でトロンビンに結合するアプタマー
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
KR102596343B1 (ko) * 2016-11-23 2023-10-31 베를린 큐어스 게엠베하 TLR9 활성화의 저해 및/또는 억제에 사용되는 압타머(aptamer)

Also Published As

Publication number Publication date
US12606828B2 (en) 2026-04-21
BR112022020439A2 (pt) 2022-11-29
IL297155A (en) 2022-12-01
JP2023521361A (ja) 2023-05-24
CA3175067A1 (en) 2021-10-14
MX2022012618A (es) 2022-11-07
CN115768895A (zh) 2023-03-07
ZA202212179B (en) 2025-03-26
KR20220166337A (ko) 2022-12-16
EP4133083A1 (en) 2023-02-15
US20230140490A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
US20230331837A1 (en) Oligonucleotides for reduction of pd-l1 expression
US12606828B2 (en) Aptamers for use in the treatment of Coronaviridae infections
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
WO2021205012A1 (en) Aptamers for use in the treatment of coronaviridae infections
EP2683826B1 (en) Use of aptamers in therapy and/or diagnosis of autoimmune diseases
JP2026021387A (ja) コロナウイルス科感染の治療において使用するためのアプタマー
CN120731091A (zh) 用于肝外递送的α-Vβ-6(αvβ6)整合素配体
HK40104624B (en) Aptamers for use in the treatment of coronaviridae infections
HK40104624A (en) Aptamers for use in the treatment of coronaviridae infections
CN117642179A (zh) 流感病毒核酸脂质颗粒疫苗
CN121419780A (zh) 用于抑制甲型流感病毒基因表达的RNAi试剂、其组合物和使用方法
NZ785335A (en) Oligonucleotides for reduction of pd-l1 expression